F901318 - A Phase I, Single Intravenous Dose, Safety, Tolerability and Pharmacokinetics Study in Healthy Male and Female Subjects
Latest Information Update: 15 Mar 2021
Price :
$35 *
At a glance
- Drugs Olorofim (Primary)
- Indications Aspergillosis
- Focus Pharmacokinetics
- Sponsors F2G
- 30 Oct 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 15 Mar 2017 New trial record